{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T03:41:26Z","timestamp":1793072486895,"version":"4.5.0"},"reference-count":48,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,7,14]],"date-time":"2022-07-14T00:00:00Z","timestamp":1657756800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"abstract":"<jats:p>Uric acid (UA) is the final product of purine metabolism in the human body, and impaired purine metabolism can increase the uric acid in serum, finally resulting in hyperuricemia (HUA). Current evidences suggest that urates might have antioxidant properties under certain circumstances, but most evidences suggest that urates promote inflammation. Hyperuricemia leads to the formation of urate crystals, which might be recognized as a red flag by the immune system. Such a response stimulates macrophage activation, leads to the activation of NOD-like receptor protein 3 (NLRP3) inflammasome vesicles, and ultimately the production and liberation of interleukin-1b (IL-1b) and interleukin-18 (IL-18), which can mediate inflammation, apoptosis and necroinflammation and cause an inflammatory cascade response. The kidney is one of the most commonly affected organs in HUA, which promotes the development of chronic kidney disease (CKD) by damaging endothelial cells, activating the renin-angiotensin system (RAS), and promoting inflammatory responses. Pharmacological interventions and lifestyle modifications are the primary means for controlling gout and lowering UA. The febuxostat is safe for CKD patients in the UA lowering therapy. Although dialysis can reduce UA levels, the application of drug is also necessary for dialysis patients. This article reviews the synthesis and metabolism of UA, etiology of HUA, the relationship between HUA and kidney disease, the treatment of gout and gouty nephropathy (GN).<\/jats:p>","DOI":"10.3389\/fendo.2022.911968","type":"journal-article","created":{"date-parts":[[2022,7,14]],"date-time":"2022-07-14T05:58:22Z","timestamp":1657778302000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":117,"title":["Excess Uric Acid Induces Gouty Nephropathy Through Crystal Formation: A Review of Recent Insights"],"prefix":"10.3389","volume":"13","author":[{"given":"Yongsheng","family":"Mei","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bingzi","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhuang","family":"Geng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lili","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,7,14]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"9221","DOI":"10.3390\/ijms22179221","article-title":"Molecular Biological and Clinical Understanding of the Pathophysiology and Treatments of Hyperuricemia and Its Association With Metabolic Syndrome, Cardiovascular Diseases and Chronic Kidney Disease","volume":"22","author":"Yanai","year":"2021","journal-title":"Int J Mol Sci"},{"key":"B2","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.ijcard.2015.08.109","article-title":"Regulation of Uric Acid Metabolism and Excretion","volume":"213","author":"Maiuolo","year":"2016","journal-title":"Int J Cardiol"},{"key":"B3","doi-asserted-by":"publisher","first-page":"S2","DOI":"10.1016\/j.semarthrit.2020.04.007","article-title":"The Biology of Urate","volume":"50","author":"Keenan","year":"2020","journal-title":"Semin Arthritis Rheumatol"},{"key":"B4","doi-asserted-by":"publisher","first-page":"762820","DOI":"10.1155\/2015\/762820","article-title":"Prevalence of Hyperuricemia and Gout in Mainland China From 2000 to 2014: A Systematic Review and Meta-Analysis","volume":"2015","author":"Liu","year":"2015","journal-title":"BioMed Res Int"},{"key":"B5","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1016\/j.rdc.2014.07.002","article-title":"Gout: A Review of Nonmodifiable and Modifiable Risk Factors","volume":"40","author":"MacFarlane","year":"2014","journal-title":"Rheum Dis Clin North Am"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1038\/s41584-018-0004-x","article-title":"An Update on the Genetics of Hyperuricaemia and Gout","volume":"14","author":"Major","year":"2018","journal-title":"Nat Rev Rheumatol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1038\/ng.2352","article-title":"Meta-Analysis Identifies Multiple Loci Associated With Kidney Function-Related Traits in East Asian Populations","volume":"44","author":"Okada","year":"2012","journal-title":"Nat Genet"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.2337\/dc07-1276","article-title":"High Serum Uric Acid as a Novel Risk Factor for Type 2 Diabetes","volume":"31","author":"Dehghan","year":"2008","journal-title":"Diabetes Care"},{"key":"B9","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1007\/s10157-011-0532-z","article-title":"Recent Advances in Renal Urate Transport: Characterization of Candidate Transporters Indicated by Genome-Wide Association Studies","volume":"16","author":"Anzai","year":"2012","journal-title":"Clin Exp Nephrol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/S2665-9913(20)30221-6","article-title":"Cardiovascular Risk in Inflammatory Arthritis: Rheumatoid Arthritis and Gout","volume":"3","author":"Hansildaar","year":"2021","journal-title":"Lancet Rheumatol"},{"key":"B11","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1186\/s13075-018-1704-y","article-title":"Monosodium Urate Crystals Reduce Osteocyte Viability and Indirectly Promote a Shift in Osteocyte Function Towards a Proinflammatory and Proresorptive State","volume":"20","author":"Chhana","year":"2018","journal-title":"Arthritis Res Ther"},{"key":"B12","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1016\/j.jare.2017.04.008","article-title":"Gout: An Old Disease in New Perspective - A Review","volume":"8","author":"Ragab","year":"2017","journal-title":"J Adv Res"},{"key":"B13","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1111\/imr.12833","article-title":"Urate-Induced Immune Programming: Consequences for Gouty Arthritis and Hyperuricemia","volume":"294","author":"Cabau","year":"2020","journal-title":"Immunol Rev"},{"key":"B14","doi-asserted-by":"publisher","first-page":"7041","DOI":"10.1038\/ncomms8041","article-title":"Genome-Wide Association Analysis Identifies Three New Risk Loci for Gout Arthritis in Han Chinese","volume":"6","author":"Li","year":"2015","journal-title":"Nat Commun"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2019-215521","article-title":"Genome-Wide Association Study Revealed Novel Loci Which Aggravate Asymptomatic Hyperuricaemia Into Gout","volume":"78","author":"Kawamura","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1080\/15257770802138558","article-title":"Uric Acid: The Oxidant-Antioxidant Paradox","volume":"27","author":"Sautin","year":"2008","journal-title":"Nucleosides Nucleotides Nucleic Acids"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1152\/ajpcell.00600.2006","article-title":"Adverse Effects of the Classic Antioxidant Uric Acid in Adipocytes: NADPH Oxidase-Mediated Oxidative\/Nitrosative Stress","volume":"293","author":"Sautin","year":"2007","journal-title":"Am J Physiol Cell Physiol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0114259","article-title":"Hyperuricemia and Risk of Incident Hypertension: A Systematic Review and Meta-Analysis of Observational Studies","volume":"9","author":"Wang","year":"2014","journal-title":"PLoS One"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1016\/j.mehy.2007.06.018","article-title":"Is Uric Acid Itself a Player or a Bystander in the Pathophysiology of Chronic Heart Failure","volume":"70","author":"Duan","year":"2008","journal-title":"Med Hypotheses"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1038\/nrrheum.2015.125","article-title":"Mechanisms of Crystal Formation in Gout-a Structural Approach","volume":"11","author":"Pascual","year":"2015","journal-title":"Nat Rev Rheumatol"},{"key":"B21","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1186\/s13075-015-0610-9","article-title":"Gout and Risk of Chronic Kidney Disease and Nephrolithiasis: Meta-Analysis of Observational Studies","volume":"17","author":"Roughley","year":"2015","journal-title":"Arthritis Res Ther"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0050046","article-title":"Reduced Glomerular Function and Prevalence of Gout: NHANES 2009-10","volume":"7","author":"Krishnan","year":"2012","journal-title":"PLoS One"},{"key":"B23","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1016\/j.amjmed.2011.09.033","article-title":"Comorbidities of Gout and Hyperuricemia in the US General Population: NHANES 2007-2008","volume":"125","author":"Zhu","year":"2012","journal-title":"Am J Med"},{"key":"B24","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1007\/s11906-016-0684-z","article-title":"Hyperuricemia, Hypertension, and Chronic Kidney Disease: An Emerging Association","volume":"18","author":"Mallat","year":"2016","journal-title":"Curr Hypertens Rep"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1038\/s41584-021-00657-4","article-title":"Management of Gout in Chronic Kidney Disease: A G-CAN Consensus Statement on the Research Priorities","volume":"17","author":"Stamp","year":"2021","journal-title":"Nat Rev Rheumatol"},{"key":"B26","doi-asserted-by":"publisher","first-page":"39884","DOI":"10.1038\/srep39884","article-title":"Soluble Uric Acid Activates the NLRP3 Inflammasome","volume":"7","author":"Braga","year":"2017","journal-title":"Sci Rep"},{"key":"B27","doi-asserted-by":"publisher","first-page":"2180373","DOI":"10.1155\/2018\/2180373","article-title":"Inflammation-Related Mechanisms in Chronic Kidney Disease Prediction, Progression, and Outcome","volume":"2018","author":"Mihai","year":"2018","journal-title":"J Immunol Res"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2016.11.006","article-title":"AJKD Atlas of Renal Pathology: Gouty Nephropathy","volume":"69","author":"Lusco","year":"2017","journal-title":"Am J Kidney Dis"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1016\/j.kint.2020.08.024","article-title":"A Cross-Sectional Study of 502 Patients Found a Diffuse Hyperechoic Kidney Medulla Pattern in Patients With Severe Gout","volume":"99","author":"Bardin","year":"2021","journal-title":"Kidney Int"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)32234-0","article-title":"Long-Term Cardiovascular Safety of Febuxostat Compared With Allopurinol in Patients With Gout (FAST): A Multicentre, Prospective, Randomised, Open-Label, non-Inferiority Trial","volume":"396","author":"Mackenzie","year":"2020","journal-title":"Lancet"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1002\/art.10511","article-title":"Effect of Urate-Lowering Therapy on the Velocity of Size Reduction of Tophi in Chronic Gout","volume":"47","author":"Perez-Ruiz","year":"2002","journal-title":"Arthritis Rheumatol"},{"key":"B32","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/acr.24180","article-title":"2020 American College of Rheumatology Guideline for the Management of Gout","volume":"2020","author":"FitzGerald","year":"2020","journal-title":"Am Coll Rheumatol"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.7326\/M20-1594","article-title":"Risk for Serious Infection With Low-Dose Glucocorticoids in Patients With Rheumatoid Arthritis : A Cohort Study","volume":"173","author":"George","year":"2020","journal-title":"Ann Intern Med"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1002\/art.27327","article-title":"High Versus Low Dosing of Oral Colchicine for Early Acute Gout Flare: Twenty-Four-Hour Outcome of the First Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Comparison Colchicine Study","volume":"62","author":"Terkeltaub","year":"2010","journal-title":"Arthritis Rheumatol"},{"key":"B35","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1186\/s12916-017-0890-9","article-title":"Impact of Comorbidities on Gout and Hyperuricaemia: An Update on Prevalence and Treatment Options","volume":"15","author":"Bardin","year":"2017","journal-title":"BMC Med"},{"key":"B36","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1186\/s13075-021-02416-y","article-title":"Efficacy and Safety of Gout Flare Prophylaxis and Therapy Use in People With Chronic Kidney Disease: A Gout, Hyperuricemia and Crystal-Associated Disease Network (G-CAN)-Initiated Literature Review","volume":"23","author":"Pisaniello","year":"2021","journal-title":"Arthritis Res Ther"},{"key":"B37","doi-asserted-by":"publisher","first-page":"rkaa073","DOI":"10.1093\/rap\/rkaa073","article-title":"Efficacy and Safety of Urate-Lowering Therapy in People With Kidney Impairment: A GCAN-Initiated Literature Review","volume":"5","author":"Farquhar","year":"2021","journal-title":"Rheumatol Adv Pract"},{"key":"B38","doi-asserted-by":"publisher","first-page":"2283","DOI":"10.3390\/ijms18112283","article-title":"Xanthine Oxidase Inhibitors for Improving Renal Function in Chronic Kidney Disease Patients: An Updated Systematic Review and Meta-Analysis","volume":"18","author":"Pisano","year":"2017","journal-title":"Int J Mol Sci"},{"key":"B39","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1007\/s11883-019-0794-6","article-title":"Primary and Secondary Prevention of Cardiovascular Disease in Patients With Chronic Kidney Disease","volume":"21","author":"Ali","year":"2019","journal-title":"Curr Atheroscler Rep"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.200347","article-title":"Variability in Urate-Lowering Therapy Prescribing: A Gout, Hyperuricemia and Crystal-Associated Disease Network (G-CAN) Physician Survey","volume":"48","author":"Stamp","year":"2021","journal-title":"J Rheumatol"},{"key":"B41","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1093\/rheumatology\/kex156","article-title":"The British Society for Rheumatology Guideline for the Management of Gout","volume":"56","author":"Hui","year":"2017","journal-title":"Rheumatol (Oxford)"},{"key":"B42","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1136\/annrheumdis-2016-209707","article-title":"2016 Updated EULAR Evidence-Based Recommendations for the Management of Gout","volume":"76","author":"Richette","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1007\/s40266-018-0517-7","article-title":"Managing Gout in the Patient With Renal Impairment","volume":"35","author":"Pascual","year":"2018","journal-title":"Drugs Aging"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1002\/art.39654","article-title":"Impact of Febuxostat on Renal Function in Gout Patients With Moderate-To-Severe Renal Impairment","volume":"68","author":"Saag","year":"2016","journal-title":"Arthritis Rheumatol"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2017-211574","article-title":"Stepwise Dose Increase of Febuxostat is Comparable With Colchicine Prophylaxis for the Prevention of Gout Flares During the Initial Phase of Urate-Lowering Therapy: Results From FORTUNE-1, a Prospective, Multicentre Randomised Study","volume":"77","author":"Yamanaka","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1710895","article-title":"Cardiovascular Safety of Febuxostat or Allopurinol in Patients With Gout","volume":"378","author":"White","year":"2018","journal-title":"N Engl J Med"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1111\/imj.14163","article-title":"Serum Urate Levels and Therapy in Adults Treated With Long-Term Dialysis: A Retrospective Cross-Sectional Study","volume":"49","author":"Yeo","year":"2019","journal-title":"Intern Med J"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1007\/s00228-016-2133-y","article-title":"A Population Pharmacokinetic Model to Predict Oxypurinol Exposure in Patients on Haemodialysis","volume":"73","author":"Wright","year":"2017","journal-title":"Eur J Clin Pharmacol"}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2022.911968\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,14]],"date-time":"2022-07-14T05:58:23Z","timestamp":1657778303000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2022.911968\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,14]]},"references-count":48,"alternative-id":["10.3389\/fendo.2022.911968"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2022.911968","relation":{},"ISSN":["1664-2392"],"issn-type":[{"value":"1664-2392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,7,14]]},"article-number":"911968"}}